EW
Edwards Lifesciences Corporation NYSE Listed Mar 27, 2000$87.36
+0.78%
vs $86.68
Mkt Cap $51.2B
52w Low $72.65
92.3% of range
52w High $88.58
50d MA $83.26
200d MA $81.96
P/E (TTM)
47.7x
EV/EBITDA
33.3x
P/B
4.9x
Debt/Equity
0.1x
ROE
10.4%
P/FCF
38.3x
RSI (14)
52.60
ATR (14)
$2.34
Beta
0.94
50d MA
$83.26
200d MA
$81.96
Avg Volume
4.9M
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
One Edwards Way · Irvine, CA 92614 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 0.73 | 0.78 | +7.0% | 79.72 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% | — |
| Feb 10, 2026 | AMC | 0.62 | 0.58 | -6.1% | 77.05 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% | — |
| Oct 30, 2025 | AMC | 0.60 | 0.67 | +12.4% | 83.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% | — |
| Jul 24, 2025 | AMC | 0.62 | 0.67 | +7.4% | 75.80 | +7.5% | +5.5% | -1.9% | +2.5% | +0.9% | -2.3% | — |
| Apr 23, 2025 | AMC | 0.60 | 0.64 | +7.4% | 70.46 | +5.3% | +6.6% | +1.2% | -0.7% | +1.0% | -1.0% | — |
| Feb 11, 2025 | AMC | 0.55 | 0.59 | +7.1% | 70.91 | +4.4% | +6.9% | +0.2% | +0.3% | -0.7% | -1.3% | — |
| Oct 24, 2024 | AMC | 0.67 | 0.67 | +0.8% | 70.35 | -2.1% | -1.4% | -1.2% | +1.2% | -1.1% | -2.4% | — |
| Jul 24, 2024 | AMC | 0.69 | 0.70 | +1.4% | 86.95 | -26.4% | -31.3% | +4.5% | +2.2% | -0.2% | -0.9% | — |
| Apr 25, 2024 | AMC | 0.64 | 0.66 | +3.1% | 88.01 | -1.1% | -1.8% | -0.6% | -1.5% | -0.4% | +0.9% | — |
| Feb 6, 2024 | AMC | 0.64 | 0.64 | +0.0% | 88.25 | +1.3% | -1.9% | -0.9% | -0.9% | +2.5% | -1.0% | — |
| Oct 25, 2023 | AMC | 0.59 | 0.59 | +0.0% | 68.34 | -8.5% | -8.1% | -1.7% | +1.1% | +2.2% | +0.2% | — |
| Jul 26, 2023 | AMC | 0.65 | 0.66 | +1.5% | 91.63 | -5.1% | -9.8% | +1.3% | -2.0% | -0.0% | -2.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Barclays | Maintains | Overweight → Overweight | — | $84.15 | $83.54 | -0.7% | -0.8% | -1.4% | -1.3% | +2.8% | +0.6% |
| Apr 24 | BTIG | Maintains | Buy → Buy | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Canaccord Genuity | Maintains | Hold → Hold | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Baird | Maintains | Neutral → Neutral | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Truist | Maintains | Hold → Hold | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $77.87 | $77.57 | -0.4% | +0.3% | +0.1% | +0.0% | +1.1% | +2.5% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $81.05 | $81.00 | -0.1% | +0.2% | -0.4% | +1.1% | -3.1% | -1.6% |
| Feb 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | BTIG | Maintains | Buy → Buy | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Truist | Maintains | Hold → Hold | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Goldman Sachs | Maintains | Buy → Buy | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $84.35 | $83.73 | -0.7% | -1.1% | +2.0% | -0.8% | -0.9% | +0.7% |
| Jan 20 | Stifel | Maintains | Buy → Buy | — | $84.35 | $83.73 | -0.7% | -1.1% | +2.0% | -0.8% | -0.9% | +0.7% |
| Jan 12 | UBS | Maintains | Neutral → Neutral | — | $85.13 | $86.00 | +1.0% | -2.5% | +1.0% | -0.9% | +1.7% | -0.2% |
| Jan 12 | Barclays | Maintains | Overweight → Overweight | — | $85.13 | $86.00 | +1.0% | -2.5% | +1.0% | -0.9% | +1.7% | -0.2% |
| Jan 9 | TD Cowen | Upgrade | Hold → Buy | — | $84.58 | $85.28 | +0.8% | +0.7% | -2.5% | +1.0% | -0.9% | +1.7% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $85.85 | $86.27 | +0.5% | -1.2% | -0.3% | +0.7% | -2.5% | +1.0% |
| Dec 18 | JP Morgan | Upgrade | Neutral → Overweight | — | $84.84 | $85.83 | +1.2% | -0.0% | +1.0% | +1.0% | -0.3% | +0.1% |
| Dec 17 | Canaccord Genuity | Maintains | Hold → Hold | — | $85.32 | $85.76 | +0.5% | -0.6% | -0.0% | +1.0% | +1.0% | -0.3% |
| Dec 16 | Baird | Maintains | Neutral → Neutral | — | $83.38 | $83.16 | -0.3% | +2.3% | -0.6% | -0.0% | +1.0% | +1.0% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $83.92 | $84.35 | +0.5% | +0.4% | -1.4% | +0.4% | +2.3% | -0.6% |
| Dec 8 | Barclays | Maintains | Overweight → Overweight | — | $86.19 | $86.01 | -0.2% | -2.2% | -1.2% | +0.8% | +0.4% | -1.4% |
| Dec 5 | BTIG | Maintains | Buy → Buy | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Truist | Maintains | Hold → Hold | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Canaccord Genuity | Maintains | Hold → Hold | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | RBC Capital | Maintains | Outperform → Outperform | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Stifel | Maintains | Buy → Buy | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | UBS | Maintains | Neutral → Neutral | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Baird | Maintains | Neutral → Neutral | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Nov 25 | BTIG | Maintains | Buy → Buy | — | $84.71 | $84.66 | -0.1% | +2.5% | -0.1% | -0.1% | -1.6% | -0.7% |
| Nov 3 | Truist | Maintains | Hold → Hold | — | $82.45 | $83.41 | +1.2% | +0.8% | +1.3% | -1.6% | -0.5% | +1.2% |
| Nov 3 | Canaccord Genuity | Maintains | Hold → Hold | — | $82.45 | $83.41 | +1.2% | +0.8% | +1.3% | -1.6% | -0.5% | +1.2% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | JP Morgan | Maintains | Neutral → Neutral | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Stifel | Maintains | Buy → Buy | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Evercore ISI | Maintains | Outperform → Outperform | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Mizuho | Maintains | Outperform → Outperform | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Goldman Sachs | Maintains | Buy → Buy | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 29 | Jefferies | Upgrade | Hold → Buy | — | $82.19 | $84.50 | +2.8% | +0.6% | +1.0% | -1.2% | +0.8% | +1.3% |
| Oct 29 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $82.19 | $84.50 | +2.8% | +0.6% | +1.0% | -1.2% | +0.8% | +1.3% |
| Oct 28 | Truist | Maintains | Hold → Hold | — | $80.82 | $80.17 | -0.8% | +1.7% | +0.6% | +1.0% | -1.2% | +0.8% |
| Oct 8 | Oppenheimer | Downgrade | Outperform → Perform | — | $76.72 | $74.50 | -2.9% | -1.3% | -0.7% | -1.7% | -1.3% | +0.6% |
| Oct 7 | Evercore ISI | Upgrade | In Line → Outperform | — | $76.56 | $77.85 | +1.7% | +0.2% | -1.3% | -0.7% | -1.7% | -1.3% |
| Sep 22 | Stifel | Maintains | Buy → Buy | — | $74.41 | $74.20 | -0.3% | -0.9% | +1.1% | +0.1% | +0.8% | +1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Zovighian Bernard JDir/Off | CEO | Sell | 523 | $87.92 | $46K | 11,516 | +0.78% | — |
| May 27, 2026 | BOBO DONALD E JROff | CVP,Strategy/Corp Development | Sell | 23,145 | $86.42 | $2.0M | 98,611 | -0.64% | -1.89% |
| May 18, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 620 | $81.14 | $50K | 40,410 | -0.28% | +2.05% |
| May 15, 2026 | BOBO DONALD E JROff | CVP,Strategy/Corp Development | Sell | 8,000 | $81.82 | $655K | 30,969 | -0.28% | +2.05% |
| May 15, 2026 | BOBO DONALD E JROff | CVP,Strategy/Corp Development | Sell | 9,968 | $82.07 | $818K | 22,798 | -0.28% | +2.05% |
| May 12, 2026 | Zovighian Bernard JDir/Off | CEO | Sell | 35,506 | $77.92 | $2.8M | 12,039 | +2.08% | -0.28% |
| May 12, 2026 | Zovighian Bernard JDir/Off | CEO | Sell | 845 | $78.40 | $66K | 47,545 | +2.08% | -0.28% |
| May 11, 2026 | Markowitz WayneOff | CVP, JAPAC | Sell | 593 | $79.73 | $47K | 21,679 | +3.32% | +1.24% |
| May 4, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 1,019 | $83.98 | $86K | 33,681 | -0.50% | -3.49% |
| May 1, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 1,000 | $82.99 | $83K | 33,933 | -0.50% | -3.49% |
| May 1, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 19 | $83.99 | $2K | 34,933 | -0.50% | -3.49% |
8-K
Edwards Lifesciences Corp -- 8-K Filing
Edwards Lifesciences reported Q1 2026 results, with CEO Bernard Zovighian reaffirming the company's strategic focus on structural heart disease innovation and addressing complex patient needs.
Apr 23
8-K
Edwards Lifesciences Corp -- 8-K Filing
Edwards Lifesciences reported strong fourth-quarter results and raised its 2026 outlook, citing confidence in sustained growth from its valve innovation expertise and clinical evidence.
Feb 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 37,727,792 | $3.0B | New | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 26,407,018 | $2.1B | New | Mar 2026 |
| 3 | Jpmorgan Chase & Co | 21,744,712 | $1.7B | Reduced | Mar 2026 |
| 4 | Bank Of New York Mellon Corp | 16,737,548 | $1.3B | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 14,628,584 | $1.2B | Added | Dec 2025 |
| 6 | Jennison Associates Llc | 13,780,515 | $1.2B | Reduced | Dec 2025 |
| 7 | Fmr Llc | 14,503,770 | $1.2B | Reduced | Mar 2026 |
| 8 | Ninety One Uk Ltd | 12,396,143 | $993M | Added | Mar 2026 |
| 9 | Northern Trust Corp | 5,824,369 | $466M | Reduced | Mar 2026 |
| 10 | Artisan Partners Limited Partnership | 5,201,144 | $417M | Added | Mar 2026 |
| 11 | Invesco Ltd. | 4,815,350 | $386M | Added | Mar 2026 |
| 12 | Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 4,800,000 | $384M | — | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 3,883,419 | $311M | Added | Mar 2026 |
| 14 | Primecap Management Co/ca/ | 3,422,791 | $274M | — | Mar 2026 |
| 15 | Vanguard Fiduciary Trust Co | 3,265,355 | $261M | New | Mar 2026 |
| 16 | Nuveen, Llc | 2,893,244 | $232M | Reduced | Mar 2026 |
| 17 | Amundi | 2,670,209 | $214M | New | Mar 2026 |
| 18 | Ubs Group Ag | 2,561,776 | $205M | Added | Mar 2026 |
| 19 | Liontrust Investment Partners Llp | 2,382,752 | $197M | Reduced | Mar 2026 |
| 20 | Royal Bank Of Canada | 2,446,999 | $196M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$51.18B
Enterprise Value
$47.55B
P/E (TTM)
47.74x
Forward P/E
29.07x
PEG Ratio
-0.63x
P/B
4.94x
P/S
8.43x
P/FCF
38.33x
EV/EBITDA
33.26x
Shares Out
585.8M
Financials (TTM)
Revenue
$6.07B
Net Income
$1.07B
EBITDA
$1.43B
Free Cash Flow
$1.33B
Op Cash Flow
$1.60B
EPS Basic
$1.84
EPS Diluted
$1.83
EPS Forward
$3.01
Gross Margin
78.1%
Op Margin
27.0%
Net Margin
17.7%
Balance Sheet
Total Assets
$13.70B
Total Liab.
$3.36B
Total Equity
$10.34B
Cash
$4.23B
LT Debt
$598.3M
Book Value/Sh
$17.68
Debt/Equity
0.07x
Current Ratio
3.72
Quick Ratio
3.09
Returns & Growth
ROE
10.4%
ROA
7.8%
ROIC
11.4%
Rev Growth YoY
+11.6%
EPS Growth YoY
-73.6%
Price Returns
2W
+6.3%
1M
+3.6%
3M
+0.0%
6M
-0.2%
12M
+10.5%
Technicals
52W High
$88.58
52W Low
$72.65
50d MA
$83.26
200d MA
$81.96
RSI (14)
52.60
ATR (14)
$2.34
Beta
0.94
Avg Volume
4.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$96.25
High
$110.00
Low
$85.00
Median
$95.00
Data updated apr 25, 2026 8:05am
· Source: financialmodelingprep.com